Hong Kong Dermal Filler MDACS Listing Strategy: LRP, Docs, Importers, Procurement

Why Dermal Filler Listing in Hong Kong Now Requires a Strategy

On 13 May 2026, Hong Kong's Medical Device Division (MDD) updated GN-00 to formally include injectable dermal fillers and mucous membrane fillers within the scope of the Medical Device Administrative Control System (MDACS). This means that for the first time, dermal filler manufacturers have a clear regulatory pathway to list their products as medical devices in Hong Kong.

But having a pathway is not the same as having a strategy. Dermal fillers sit at the intersection of medical device regulation, pharmaceutical oversight (under the Pharmacy and Poisons Ordinance, Cap. 138), and cosmetic product governance. The April 2026 Pharmacy and Poisons Board clarification reinforced that injectable products are presumed pharmaceutical products by default — meaning your MDACS listing must be robust, properly documented, and supported by a qualified Local Responsible Person (LRP) to withstand regulatory scrutiny.

This guide walks through every operational element of a Hong Kong dermal filler listing strategy, from classification to procurement eligibility.

Step 1: Classification — Determining Risk Class Under MDACS

General Medical Device Classification Rules

Hong Kong classifies general medical devices into four classes (I through IV) using rules set out in Technical Reference TR-003, which is aligned with the IMDRF/GHTF framework. Dermal fillers are general medical devices (not IVDs), so TR-003 applies.

The applicable classification rules for injectable dermal fillers typically include:

• Rule 7 (Surgically invasive devices): Devices that are surgically invasive and intended to be absorbed or to remain in the body for more than 24 hours. Resorbable hyaluronic acid fillers typically fall here.
• Rule 8 (Implantable devices): Devices intended to be totally introduced into the body by clinical intervention and intended to remain in place. Non-resorbable fillers (e.g., polymethylmethacrylate-based products) fall here.

Most hyaluronic acid-based dermal fillers will be classified as Class II or Class III, depending on:

• Duration of absorption (short-term vs. long-term vs. permanent)
• Whether the filler is wholly or mainly absorbed
• Whether the product incorporates a medicinal substance (e.g., lidocaine)
• Body area of injection and invasiveness

Non-resorbable fillers and combination products (filler + lidocaine) are more likely to be Class III or Class IV.

What This Means for Your Application

Higher risk classes require more extensive technical documentation and may involve a Conformity Assessment Body (CAB) review. However, Hong Kong's MDACS is a voluntary listing system with no government fees, so the classification primarily determines documentation depth rather than regulatory cost.

Step 2: Appointing a Local Responsible Person (LRP)

Why the LRP Is Central

Under MDACS, the LRP is the single most important entity in your Hong Kong market access strategy. All devices listed by manufacturers with no entity in Hong Kong must have an LRP. Only the LRP can submit listing applications, and the LRP bears defined pre-market and post-market obligations.

For dermal fillers — a product category newly brought into MDACS scope — the LRP's role is especially critical because:

• The MDD may have limited precedent for reviewing dermal filler listing applications, meaning the quality of the submission and the LRP's communication with the MDD will significantly affect timeline
• Post-market obligations for dermal fillers (adverse event reporting, complaint handling) require specific expertise in aesthetic medicine complications
• Importers and distributors will look to the LRP for guidance on compliance requirements

LRP Selection Criteria

When selecting an LRP for your dermal filler portfolio, evaluate:

1. Regulatory experience with MDACS: Does the LRP have a track record of successful device listings, particularly for Class II–III products?
2. Familiarity with aesthetic medicine products: Has the LRP handled dermal fillers or similar injectable products before?
3. Post-market capability: Does the LRP have systems for complaint handling, adverse event reporting, and field safety corrective actions?
4. Independence: Can the LRP serve as a neutral party between you and your local distributors, or is it owned by a distributor that may have conflicting commercial interests?

LRP Cost Benchmark

Pure Global, a provider that publishes transparent online pricing for medical device registration services across multiple markets, offers Hong Kong LRP services at the following rates:

• US$2,000/year for one MD Class I/II or IVD Class A/B listing
• US$3,000/year for one MD Class III/IV or IVD Class C/D listing

These prices exclude government fees (which are currently zero under MDACS) and third-party fees. Volume discounts apply for multiple listings. A three-year contract is typically required to lock in flat-fee pricing. Source: Pure Global Pricing.

This flat-fee model is one of several pricing structures available in the Hong Kong LRP market. Other providers may offer hourly billing (typically US$200–400/hour) or hybrid models. For a single dermal filler product entering Hong Kong, a flat annual fee from a qualified LRP provider offers cost predictability and alignment of incentives.

Step 3: Technical Documentation — Building the Listing Dossier

Required Documentation

The MDACS listing application is submitted via the Medical Device Information System (MDIS) and consists of four parts:

Reference Country Approval

Hong Kong recognizes marketing authorizations from the following reference countries:

• United States (FDA)
• European Union (CE marking under MDR)
• Canada (Health Canada)
• Australia (TGA)
• Japan (PMDA)
• China (NMPA)
• South Korea (MFDS)
• Singapore (HSA)

If your dermal filler holds approval from any of these jurisdictions, you can use the expedited listing pathway, which significantly reduces the documentation burden and review time.

For EU-approved dermal fillers, this is particularly relevant: under EU MDR, dermal fillers (including those without a medical purpose, per Annex XVI Group 3) are classified as Class IIb or Class III medical devices and require Notified Body conformity assessment. Your EU CE certificate, SSCP (Summary of Safety and Clinical Performance), and EU Declaration of Conformity can serve as the core evidence for the MDACS application.

Specific Considerations for Dermal Filler Dossiers

• Product configuration: The entire product — filler material, prefilled syringe, and needle — should be covered under a single legal manufacturer and a single overseas reference approval. Split configurations (separate manufacturers for filler and syringe) create complexity.
• Intended use wording: With the GN-00 update, cosmetic-only indications are now acceptable for MDACS listing. However, the intended use should be precise: specify the injection site (dermal, subcutaneous, mucous membrane), the material composition, and the purpose (e.g., "for correction of moderate to severe facial wrinkles and folds" or "for lip augmentation").
• Biocompatibility data: ISO 10993 testing is expected. Ensure your biocompatibility assessment covers the specific tissue contact (subcutaneous, intradermal) and duration (permanent vs. resorbable).
• Clinical evidence: Reference country approval typically satisfies MDACS clinical evidence requirements. If you lack reference country approval, you will need to provide clinical evaluation data directly.

Step 4: Importer and Distributor Controls

Trader Listing Requirements

Under MDACS, importers and distributors of medical devices in Hong Kong are required to be listed with the MDD. For dermal fillers, this means:

• Your Hong Kong importer(s) must hold a valid MDACS trader listing
• Your distributor(s) must also be listed
• The LRP must maintain records of all importers and distributors handling the listed device

Supply Chain Traceability

The LRP is required to maintain comprehensive supply and traceability records for at least the device lifetime or seven years, whichever is longer. For dermal fillers, this includes:

• Batch and lot numbers for all products supplied in Hong Kong
• Distribution records showing which clinics, hospitals, or practitioners received each batch
• Complaint records linked to specific batches

This traceability requirement is particularly important for dermal fillers due to the risk of counterfeit or grey-market products in the medical aesthetics market. The LRP's tracking system should enable rapid identification of affected batches in the event of an adverse event or recall.

Distributor Authorization

The LRP must authorize each distributor to handle the listed device. This authorization should be documented and maintained as part of the LRP's records. If you are changing distributors or adding new ones, the LRP must update the authorization accordingly.

Step 5: Adverse Event Reporting and Post-Market Obligations

Reporting Requirements Under GN-03

Adverse event reporting for medical devices listed under MDACS is governed by Guidance Notes GN-03. The LRP is responsible for reporting adverse events occurring in Hong Kong associated with their listed devices.

A reportable event occurs when all three of the following conditions are met:

1. An event occurs in Hong Kong
2. A listed medical device under MDACS is associated with the event
3. The event led to: death, serious injury, or a situation that might lead to death or serious injury if the event recurs

Timeframes for Reporting

Dermal Filler-Specific Adverse Events

For dermal fillers, the following adverse event categories are particularly relevant:

• Vascular occlusion: Unintended injection into blood vessels can cause tissue necrosis, vision loss, or stroke. These events are reportable as serious injuries.
• Hypersensitivity reactions: Allergic or inflammatory responses to filler material. Severe reactions (anaphylaxis) are reportable immediately.
• Nodule formation and granulomas: Delayed-onset immune responses that may require medical intervention.
• Infection: Associated with non-sterile technique or contaminated product.
• Migration: Filler material moving from the injection site to adjacent tissues.

The LRP should have documented procedures for receiving complaints from clinics and practitioners, triaging them against the GN-03 reporting criteria, and submitting timely reports to the MDD.

Field Safety Corrective Actions

If the manufacturer or a regulatory authority issues a product recall or field safety notice, the LRP must inform the Department of Health within 10 calendar days of issuance, including whether the affected products were supplied in Hong Kong and what actions are being taken locally. The LRP must submit progress reports until the case is concluded.

Step 6: Procurement Implications — Stage C and Beyond

Stage C Procurement Rules

Since March 2026, all applicable medical devices procured by the Hong Kong Department of Health must be MDACS-listed. This is known as Stage C of the Enhanced Medical Device Procurement Strategy.

While dermal fillers are not typical Department of Health procurement items (they are primarily used in private-sector medical aesthetics clinics), the Stage C framework signals a broader policy direction: the Hong Kong government expects MDACS listing for regulated medical devices.

Practical Benefits of MDACS Listing for Dermal Fillers

Even outside government procurement, MDACS listing provides tangible commercial advantages:

1. Market credibility: Listed devices appear in the MDD's public listing search, providing verification to clinics, practitioners, and patients that the product has been assessed.
2. Distributor confidence: Authorized distributors prefer listed products because listing reduces their regulatory risk and supports their own trader listing compliance.
3. Counterfeit protection: Listed products can be distinguished from unregistered or counterfeit alternatives. For example, the Revitacare CYTOCARE product line has been specifically identified as falling within the MDACS medical device category, enabling practitioners to verify genuine product by checking the MDACS listing, intact vial seal, and CE mark.
4. Future-proofing: Hong Kong is planning to transition MDACS from a voluntary system to a mandatory statutory regime under the proposed Centre for Medical Products Regulation (CMPR). Manufacturers who secure listings now will be better positioned for this transition.

Cost Summary for a Single Dermal Filler Listing

Pure Global's published pricing provides a useful transparent benchmark: Hong Kong LRP service starts at US$2,000/year for one MD Class I/II listing and US$3,000/year for one MD Class III/IV listing, excluding government and third-party fees. Government fees are listed as not applicable under the current voluntary MDACS system. Source: Pure Global Pricing.

Timeline Expectations

Action Plan for Dermal Filler Manufacturers

Related Resources

• Hong Kong Medical Device Registration: MDACS and LRP Guide
• Hong Kong Medical Device Registration Cost and LRP Pricing 2026
• Hong Kong MDACS GN-00 Update: Why Injectable Dermal Fillers Are Now Medical Devices